Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Tiny Implantable Battery Shrinks Tumor Size By 99% In Two Weeks

By HospiMedica International staff writers
Posted on 30 May 2025

A groundbreaking biobattery has demonstrated its ability to reduce tumor growth and may offer a new, drug-free approach to immunotherapy treatment for cancer patients. More...

The tiny implantable biobattery, developed through a global collaboration between researchers at the University of Wollongong (UOW, NSW, Australia) and Jilin University (Changchun, China), successfully shrank tumors by 99% in just two weeks during laboratory tests. The research builds on the team's earlier advancements in biobattery technology, with these results showing strong potential for cancer treatment. Biobatteries share the same basic components as conventional batteries – two electrodes (anode and cathode), a separator, and an electrolyte – but instead of traditional electricity generation, they harness biological processes to produce power. Published in Science Advances, the study explores how these biobatteries can target tumors and trigger localized immune responses in the body. When the biobattery is activated, electrons are released from the anode and travel to the cathode, where they are consumed, accompanied by chemical reactions that stimulate the body's immune system.

When the biobattery was placed around subcutaneous tumor sites, those occurring between the skin and muscle, it reduced the tumor size from over 1,000 mm³ to just 4 mm³, a dramatic reduction of 99.6% in 14 days. The release of zinc and manganese ions played a crucial role in enabling the immune system to locate and destroy cancer cells. While the battery’s current alone is capable of slowing tumor growth, the targeted release of metal ions dramatically enhances the effect, stimulating immunotherapy – a potent and effective treatment for cancer. This breakthrough opens the door to treating tumors without relying on harsh drugs, which could minimize side effects and improve patients’ quality of life. The team’s next objective is to advance the biobattery through preclinical and clinical research to bring this innovation into clinical practice.

“In this research, the by-products of battery discharge – zinc and manganese ions – create a chemical environment that inhibits tumor growth,” said UOW Distinguished Professor Gordon Wallace. "If we are clever with electrode choice, biobatteries can be more effective in treating medical conditions, including mobilizing the body’s immune response and shrinking tumors.”

“This work demonstrates a powerful electrochemical tool for drug-free cancer immunotherapy, which may open an avenue for sustained and targeted delivery of substances that activate the immune system,” added Jia Xiaoteng, Associate Professor at Jilin University.

 


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Pediatric Mask
Respire SOFT
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.